Trials360 Achieves Milestone in Phase 2b Clinical Trial for Acute Stroke Patients
Acute stroke and intracerebral hemorrhages represent some of the most common admissions in neurological intensive care units. Effective management of these conditions is crucial for achieving better patient outcomes and alleviating the substantial burden on families and society. One critical aspect of this management is ensuring the proper volume and concentration of intravenous (IV) fluids, which are essential for maintaining adequate blood flow to the brain.
Proper fluid management can significantly influence the recovery trajectory of stroke patients, underscoring the importance of our study. The insights gained from this trial are poised to enhance treatment protocols and improve the quality of care for those affected by acute stroke.
We are thrilled to announce that Trials360 has successfully completed Phase 2B clinical trial in acute stroke patients. This significant milestone marks a critical advancement in the treatment of acute stroke, bringing hope to patients and healthcare providers alike.
Our randomized, blinded, placebo-controlled Phase 2B clinical trials were meticulously designed to compare the efficacy of various combinations of fluids along with the standard care of treatment in acute stroke patients. The study was sponsored by a renowned organization from the USA and conducted at the prestigious Aga Khan University, Department of Neurology, in Karachi.
We extend our heartfelt gratitude to all the participants, researchers, and collaborators who made this achievement possible. Stay tuned for more updates as we continue our mission to advance medical research and improve patient care.
